We're pleased to announce:
📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction
📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150
At #EASCongress2026, we presented late-breaking preclinical data on our lead cardiometabolic program STX-1150. These data support STX-1150 as a clinical-stage epigenetic silencing therapy designed to achieve years of LDL-C lowering after a single dose.
Study highlights below ⬇️
#EASCongress2026 has kicked off! A late-breaking oral presentation from our CEO @BenjaminLOakes will showcase preclinical data for STX-1150, our epigenetic silencing therapy that’s designed for durable LDL-C reduction & now in the clinic.
Thanks to @EASCongress for featuring it!
📰 @theheraldsun article: https://t.co/DNzkutZx7k
🎤 If you're at #EASCongress2026 on Monday, May 25, check out the late-breaking oral presentation by Scribe co-founder and CEO @BenjaminLOakes, highlighting our preclinical data for STX-1150: https://t.co/mApxYNLX4c
@EASCongress
In @theheraldsun, Dr. Stephen Nicholls of @MonashVHI, Victorian Heart Hospital, and the PI leading Scribe's clinical trial shares his perspective on our epigenetic silencing drug STX-1150 and the need for improved therapies for cardiovascular disease. Links in thread ⬇️
Announcing our first clinical trial.
Scribe has secured regulatory clearance from Australia’s @TGAgovau to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD).
Details🧵
STX-1150 is designed to epigenetically silence PCSK9 in the liver and deliver sustained LDL-C reduction after a single dose without permanently altering DNA, with the goal of enabling early and durable ASCVD risk reduction in patients.
Link to our full announcement below ❤️🩹
♥️ How our CRISPR by Design engineering approach integrates engineering of both the XE foundation to ELXR silencing machinery to enable Scribe’s lead cardiometabolic asset for LDL-C lowering
@ASGCTherapy#CRISPR#EpigeneticEditing#GeneEditing
At #ASGCT2026, we presented preclinical data highlighting the latest advances across our engineered #CRISPR technologies for epigenetic silencing and gene editing.
Highlights of our three oral presentations below and in thread 🧵
https://t.co/9YkjgQr8k5
🧬 Allosteric ELXR epigenetic silencers designed to improve specificity while still achieving potent and durable target repression
⚒️ XE gene editing engineering advancements, supported by mechanistic insights into guide potency and AI-enabled predictive modeling through DeepXE
Two #ASGCT26 oral presentations tomorrow!
🔹Engineering CasX for therapeutic-grade in vivo editing with DeepXE, a predictive model for guide potency
🔹ADDing a lock to epigenome editing: DNMT3A allostery enhances specificity and potency of CRISPR-CasX-based epigenetic repressors
We’re kicking off #ASGCT2026 today with a workshop by co-founder & VP of External Innovation @BStaahl. Details below & more to come at @ASGCTherapy later this week!
🔹Engineering CasX from clay to clinic: lessons in precision, potency, and translatability
🕒 May 11 at 3:07 pm ET
📊At #EASCongress2026, our late-breaker will report preclinical data for STX-1150, our PCSK9-targeting epigenetic silencing therapy for LDL-C lowering.
🔗 For more details, read our press release: https://t.co/5DzF6sr0fs